Scholarly Journals--Published

  • Sherman, M. A., Pak, K., Pinal-Fernandez, I., Flegel, W. A., Targoff, I. N., Miller, F. W., ... & White, P. H. (2023). Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis & Rheumatology.   I am part of the Childhood Myositis Heterogeneity Collaborative Study Group (03/2023) (link)
  • Sherman, M. A., Graf, R., Sabbagh, S. E., Galindo-Feria, A. S., Pinal-Fernandez, I., Pak, K., ... & Mammen, A. L. (2023). Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology62(SI2), SI226-SI234 I am part of the Childhood Myositis Heterogeneity Collaborative Study Group         (02/2023) (link)
  • Castillo R D, De la Pena W, & Marzan K A B. (2013). Diagnosis and Management of Infectious Complications of Childhood Rheumatic Diseases. Current Rheumatology Reports, 15(4), 10. Progress in the diagnosis and management of pediatric rheumatic disease has improved complications from underlying disease and the survival of children. However, as a consequence, infection has now become one of the leading causes of morbidity and mortality. Differentiating between infections and disease flares in children with rheumatic conditions can often pose diagnostic quandaries. Children with rheumatic diseases are at risk of infection, not only because of the use of immune-modulating medications but also because of underlying immune dysfunction associated with their disease. Although bacterial infections are the most common, any organism can potentially be a causative agent and, at times, more invasive measures of diagnosis, for example bronchoscopy and tissue biopsiesmay be necessary. Maintaining a high index of suspicion of infection with prompt diagnosis and treatment are important to further improve patient outcomes. (04/2013) (link)


  • A Rheumatology-Driven Protocol and treatment algorithm of Sars-CoV-2 Cytokine Release Syndrome and its Associated Outcomes   abstract Number:0592 at the ACR convergence Nov 2020 meeting Lee S, Chiruvolu N, Karim M, Injean P, Doo L, Jose D, Panikkath D, Yu M, Lafian A, De La Pena W, Chow A, Torralba K, Sandhu V, Hojjati M, Cabling M, Downey C. A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). Accessed December 9, 2020 (12/2020)
  • Tofacitinib for the treatment of patients wtih Juvenile Idiopathic Arthritis: An interim analysis of data up to 5.5 years from an open-label, long-term extension study American College of Rheumatology Convergence Meeting Novemeber 2020 - Presented by Dr. Brunner Presentation No: 1495 Objective:  To assess tofacitinib safety and tolerability up to 66 months, and efficacy up to 18 months, in patients with JIA enrolled in an ongoing LTE study Conclusion:  In the open-label LTE study, the safety profile of tofacitinib in patients with JIA was consistent with that seen in patients with Rheumatoid arthritis.  No new safety findings wer observed over 66  months.   clinical efficacy was maintained over 18 months with the improvements in disease activity, physcial functioning and JIA/ACR response rates   Brunner H, Akikusa J, Al-Abadi E, Bohnsack J, Boteanu A, Chedeville G, Cuttica R, De La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert G, Neiva C, Rivas-Chacon R, Cruz Rizo Rodriguez J, Vazquez-Del Mercado M, Wagner-Weiner L, Weiss J, Wouters C, Suehiro R, Posner H, Wouters A, Kanik K, Luo Z, Martini A, Lovell D, Ruperto N. Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). Accessed December 9, 2020   (12/2020)